AU5337499A - Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments - Google Patents

Info

Publication number

AU5337499A

AU5337499A AU53374/99A AU5337499A AU5337499A AU 5337499 A AU5337499 A AU 5337499A AU 53374/99 A AU53374/99 A AU 53374/99A AU 5337499 A AU5337499 A AU 5337499A AU 5337499 A AU5337499 A AU 5337499A

Authority

AU

Australia

Prior art keywords

group

receptor

composition

receptors

adenosine

Prior art date

1998-08-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title claims description 303
• 108091034117 Oligonucleotide Proteins 0.000 title claims description 230
• 239000003795 chemical substances by application Substances 0.000 title claims description 187
• 229960005305 adenosine Drugs 0.000 title claims description 153
• 239000002126 C01EB10 - Adenosine Substances 0.000 title claims description 152
• 239000000074 antisense oligonucleotide Substances 0.000 title claims description 152
• 238000012230 antisense oligonucleotides Methods 0.000 title claims description 152
• 239000000203 mixture Substances 0.000 title claims description 123
• 238000011282 treatment Methods 0.000 title description 41
• 108020003175 receptors Proteins 0.000 claims description 158
• 102000005962 receptors Human genes 0.000 claims description 155
• 230000000692 anti-sense effect Effects 0.000 claims description 134
• 238000000034 method Methods 0.000 claims description 105
• 239000012634 fragment Substances 0.000 claims description 96
• 108020004999 messenger RNA Proteins 0.000 claims description 90
• 102000039446 nucleic acids Human genes 0.000 claims description 86
• 108020004707 nucleic acids Proteins 0.000 claims description 86
• 150000007523 nucleic acids Chemical class 0.000 claims description 85
• 108090000623 proteins and genes Proteins 0.000 claims description 73
• 230000000694 effects Effects 0.000 claims description 64
• -1 Cyclophillins Proteins 0.000 claims description 57
• 238000009472 formulation Methods 0.000 claims description 54
• 239000002773 nucleotide Substances 0.000 claims description 47
• 125000003729 nucleotide group Chemical group 0.000 claims description 47
• 201000010099 disease Diseases 0.000 claims description 46
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
• 210000004072 lung Anatomy 0.000 claims description 44
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 41
• 241001465754 Metazoa Species 0.000 claims description 38
• 239000000443 aerosol Substances 0.000 claims description 35
• 125000001072 heteroaryl group Chemical group 0.000 claims description 31
• 208000006673 asthma Diseases 0.000 claims description 29
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 28
• 239000002245 particle Substances 0.000 claims description 28
• 239000004094 surface-active agent Substances 0.000 claims description 27
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
• 102000004169 proteins and genes Human genes 0.000 claims description 23
• 206010028980 Neoplasm Diseases 0.000 claims description 21
• 229940104230 thymidine Drugs 0.000 claims description 21
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 20
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 20
• 210000004027 cell Anatomy 0.000 claims description 20
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 19
• 206010006482 Bronchospasm Diseases 0.000 claims description 18
• 230000007885 bronchoconstriction Effects 0.000 claims description 17
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
• 239000000243 solution Substances 0.000 claims description 16
• 108091008927 CC chemokine receptors Proteins 0.000 claims description 15
• 102000005674 CCR Receptors Human genes 0.000 claims description 15
• 206010061218 Inflammation Diseases 0.000 claims description 15
• 102000040945 Transcription factor Human genes 0.000 claims description 15
• 108091023040 Transcription factor Proteins 0.000 claims description 15
• 239000000556 agonist Substances 0.000 claims description 15
• 125000003118 aryl group Chemical group 0.000 claims description 15
• 210000003169 central nervous system Anatomy 0.000 claims description 15
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
• 230000004054 inflammatory process Effects 0.000 claims description 15
• 150000003212 purines Chemical class 0.000 claims description 15
• 102000000589 Interleukin-1 Human genes 0.000 claims description 14
• 108010002352 Interleukin-1 Proteins 0.000 claims description 14
• 150000003230 pyrimidines Chemical class 0.000 claims description 14
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 14
• 102100025390 Integrin beta-2 Human genes 0.000 claims description 13
• 239000002253 acid Substances 0.000 claims description 13
• 239000003814 drug Substances 0.000 claims description 13
• 102000004190 Enzymes Human genes 0.000 claims description 12
• 108090000790 Enzymes Proteins 0.000 claims description 12
• 102000004890 Interleukin-8 Human genes 0.000 claims description 12
• 108090001007 Interleukin-8 Proteins 0.000 claims description 12
• 108700020796 Oncogene Proteins 0.000 claims description 12
• 229940088598 enzyme Drugs 0.000 claims description 12
• 229920001184 polypeptide Polymers 0.000 claims description 12
• 230000002829 reductive effect Effects 0.000 claims description 12
• 239000000725 suspension Substances 0.000 claims description 12
• XHKBGMVHFNBPCD-IAMFDIQRSA-N (2r,3s)-2-(hydroxymethyl)-5-(5-nitro-1h-indol-2-yl)oxolan-3-ol Chemical compound C1[C@H](O)[C@@H](CO)OC1C1=CC2=CC([N+]([O-])=O)=CC=C2N1 XHKBGMVHFNBPCD-IAMFDIQRSA-N 0.000 claims description 11
• 230000003213 activating effect Effects 0.000 claims description 11
• 201000011510 cancer Diseases 0.000 claims description 11
• 230000003834 intracellular effect Effects 0.000 claims description 11
• 239000007787 solid Substances 0.000 claims description 11
• 238000002560 therapeutic procedure Methods 0.000 claims description 11
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 10
• 102000000585 Interleukin-9 Human genes 0.000 claims description 10
• 108010002335 Interleukin-9 Proteins 0.000 claims description 10
• 102000043276 Oncogene Human genes 0.000 claims description 10
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
• 125000000304 alkynyl group Chemical group 0.000 claims description 10
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 10
• 125000001475 halogen functional group Chemical group 0.000 claims description 10
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
• 229940118526 interleukin-9 Drugs 0.000 claims description 10
• 239000006199 nebulizer Substances 0.000 claims description 10
• 210000000653 nervous system Anatomy 0.000 claims description 10
• 230000002093 peripheral effect Effects 0.000 claims description 10
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
• 206010020751 Hypersensitivity Diseases 0.000 claims description 9
• 102000009438 IgE Receptors Human genes 0.000 claims description 9
• 102000003815 Interleukin-11 Human genes 0.000 claims description 9
• 108090000177 Interleukin-11 Proteins 0.000 claims description 9
• 108010002386 Interleukin-3 Proteins 0.000 claims description 9
• 102000001400 Tryptase Human genes 0.000 claims description 9
• 108060005989 Tryptase Proteins 0.000 claims description 9
• 125000003342 alkenyl group Chemical group 0.000 claims description 9
• 125000000217 alkyl group Chemical group 0.000 claims description 9
• 239000005557 antagonist Substances 0.000 claims description 9
• 230000015556 catabolic process Effects 0.000 claims description 9
• 238000001727 in vivo Methods 0.000 claims description 9
• 229940074383 interleukin-11 Drugs 0.000 claims description 9
• 229940076264 interleukin-3 Drugs 0.000 claims description 9
• 239000007788 liquid Substances 0.000 claims description 9
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 8
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 8
• 102100023688 Eotaxin Human genes 0.000 claims description 8
• 101710139422 Eotaxin Proteins 0.000 claims description 8
• 102000000543 Histamine Receptors Human genes 0.000 claims description 8
• 108010002059 Histamine Receptors Proteins 0.000 claims description 8
• 108060003951 Immunoglobulin Proteins 0.000 claims description 8
• 102000003800 Selectins Human genes 0.000 claims description 8
• 108090000184 Selectins Proteins 0.000 claims description 8
• 125000002252 acyl group Chemical group 0.000 claims description 8
• 230000007815 allergy Effects 0.000 claims description 8
• 102000018358 immunoglobulin Human genes 0.000 claims description 8
• 229940072221 immunoglobulins Drugs 0.000 claims description 8
• 108010024212 E-Selectin Proteins 0.000 claims description 7
• 102100023471 E-selectin Human genes 0.000 claims description 7
• 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 7
• 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 7
• 241000124008 Mammalia Species 0.000 claims description 7
• 239000002775 capsule Substances 0.000 claims description 7
• 230000001413 cellular effect Effects 0.000 claims description 7
• 238000006731 degradation reaction Methods 0.000 claims description 7
• 239000000843 powder Substances 0.000 claims description 7
• AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 7
• 239000000126 substance Substances 0.000 claims description 7
• 229960000278 theophylline Drugs 0.000 claims description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
• WJBNIBFTNGZFBW-DJLDLDEBSA-N 2'-deoxynebularine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 WJBNIBFTNGZFBW-DJLDLDEBSA-N 0.000 claims description 6
• MPQODCRXMAXIRX-UHFFFAOYSA-N 6-n-methoxy-7h-purine-2,6-diamine Chemical compound CONC1=NC(N)=NC2=C1NC=N2 MPQODCRXMAXIRX-UHFFFAOYSA-N 0.000 claims description 6
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 6
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 6
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 6
• 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 6
• ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 claims description 6
• 102000014914 Carrier Proteins Human genes 0.000 claims description 6
• 102000009410 Chemokine receptor Human genes 0.000 claims description 6
• 108050000299 Chemokine receptor Proteins 0.000 claims description 6
• 102000019034 Chemokines Human genes 0.000 claims description 6
• 108010012236 Chemokines Proteins 0.000 claims description 6
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 6
• 108010038452 Interleukin-3 Receptors Proteins 0.000 claims description 6
• 102000010790 Interleukin-3 Receptors Human genes 0.000 claims description 6
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 6
• 108010035766 P-Selectin Proteins 0.000 claims description 6
• 208000026935 allergic disease Diseases 0.000 claims description 6
• 239000003963 antioxidant agent Substances 0.000 claims description 6
• 235000006708 antioxidants Nutrition 0.000 claims description 6
• RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims description 6
• GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims description 6
• 230000003511 endothelial effect Effects 0.000 claims description 6
• 239000002502 liposome Substances 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 230000004936 stimulating effect Effects 0.000 claims description 6
• 230000008685 targeting Effects 0.000 claims description 6
• 230000002227 vasoactive effect Effects 0.000 claims description 6
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 5
• VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 claims description 5
• HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 claims description 5
• OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 claims description 5
• NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 claims description 5
• 101710085045 B2 bradykinin receptor Proteins 0.000 claims description 5
• 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 5
• 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 5
• 108010055166 Chemokine CCL5 Proteins 0.000 claims description 5
• 101800004490 Endothelin-1 Proteins 0.000 claims description 5
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
• 102000004388 Interleukin-4 Human genes 0.000 claims description 5
• 108090000978 Interleukin-4 Proteins 0.000 claims description 5
• 102000000743 Interleukin-5 Human genes 0.000 claims description 5
• 108010002616 Interleukin-5 Proteins 0.000 claims description 5
• 108010038484 Interleukin-5 Receptors Proteins 0.000 claims description 5
• 102000010786 Interleukin-5 Receptors Human genes 0.000 claims description 5
• 108010038414 Interleukin-9 Receptors Proteins 0.000 claims description 5
• 102000010682 Interleukin-9 Receptors Human genes 0.000 claims description 5
• 102000015696 Interleukins Human genes 0.000 claims description 5
• 108010063738 Interleukins Proteins 0.000 claims description 5
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 5
• 102000043136 MAP kinase family Human genes 0.000 claims description 5
• 108091054455 MAP kinase family Proteins 0.000 claims description 5
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 5
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 5
• 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 5
• 102100023472 P-selectin Human genes 0.000 claims description 5
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 5
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 5
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 5
• 229950003769 acefylline Drugs 0.000 claims description 5
• 230000001476 alcoholic effect Effects 0.000 claims description 5
• 125000005024 alkenyl aryl group Chemical group 0.000 claims description 5
• 125000003545 alkoxy group Chemical group 0.000 claims description 5
• 125000002877 alkyl aryl group Chemical group 0.000 claims description 5
• 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 5
• 125000005025 alkynylaryl group Chemical group 0.000 claims description 5
• 125000003435 aroyl group Chemical group 0.000 claims description 5
• 125000005251 aryl acyl group Chemical group 0.000 claims description 5
• 125000005018 aryl alkenyl group Chemical group 0.000 claims description 5
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
• 125000005015 aryl alkynyl group Chemical group 0.000 claims description 5
• 125000004350 aryl cycloalkyl group Chemical group 0.000 claims description 5
• 125000005110 aryl thio group Chemical group 0.000 claims description 5
• VVUYEFBRTFASAH-UHFFFAOYSA-N bamifylline Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CCN(CCO)CC)C=1CC1=CC=CC=C1 VVUYEFBRTFASAH-UHFFFAOYSA-N 0.000 claims description 5
• 229960005176 bamifylline Drugs 0.000 claims description 5
• 229960001948 caffeine Drugs 0.000 claims description 5
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 5
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
• 125000000000 cycloalkoxy group Chemical group 0.000 claims description 5
• VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 claims description 5
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 5
• 229960002819 diprophylline Drugs 0.000 claims description 5
• KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 claims description 5
• SIQPXVQCUCHWDI-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=C1NC=N2 SIQPXVQCUCHWDI-UHFFFAOYSA-N 0.000 claims description 5
• 229950000579 enprofylline Drugs 0.000 claims description 5
• 229960005387 etofylline Drugs 0.000 claims description 5
• 239000000796 flavoring agent Substances 0.000 claims description 5
• 239000003102 growth factor Substances 0.000 claims description 5
• 125000003106 haloaryl group Chemical group 0.000 claims description 5
• 125000005347 halocycloalkyl group Chemical group 0.000 claims description 5
• 102000002467 interleukin receptors Human genes 0.000 claims description 5
• 108010093036 interleukin receptors Proteins 0.000 claims description 5
• 229940100601 interleukin-6 Drugs 0.000 claims description 5
• 108010038415 interleukin-8 receptors Proteins 0.000 claims description 5
• 102000010681 interleukin-8 receptors Human genes 0.000 claims description 5
• 229940047122 interleukins Drugs 0.000 claims description 5
• 150000002632 lipids Chemical class 0.000 claims description 5
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 5
• 210000001616 monocyte Anatomy 0.000 claims description 5
• 229960005141 piperazine Drugs 0.000 claims description 5
• 150000003141 primary amines Chemical class 0.000 claims description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
• 210000002345 respiratory system Anatomy 0.000 claims description 5
• 150000003335 secondary amines Chemical class 0.000 claims description 5
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 5
• 230000009885 systemic effect Effects 0.000 claims description 5
• 150000003512 tertiary amines Chemical class 0.000 claims description 5
• 239000003981 vehicle Substances 0.000 claims description 5
• 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 4
• 101710112613 C-C motif chemokine 13 Proteins 0.000 claims description 4
• 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 4
• 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 4
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
• 102000001327 Chemokine CCL5 Human genes 0.000 claims description 4
• 108090000227 Chymases Proteins 0.000 claims description 4
• 102100031506 Complement C5 Human genes 0.000 claims description 4
• 101000936738 Coturnix japonica Astacin-like metalloendopeptidase Proteins 0.000 claims description 4
• 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 claims description 4
• 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 claims description 4
• 102100037362 Fibronectin Human genes 0.000 claims description 4
• 108010067306 Fibronectins Proteins 0.000 claims description 4
• 102000004610 GATA3 Transcription Factor Human genes 0.000 claims description 4
• 108010003338 GATA3 Transcription Factor Proteins 0.000 claims description 4
• 101000941598 Homo sapiens Complement C5 Proteins 0.000 claims description 4
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 4
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 4
• 102100022338 Integrin alpha-M Human genes 0.000 claims description 4
• 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 4
• 108010092694 L-Selectin Proteins 0.000 claims description 4
• 102100033467 L-selectin Human genes 0.000 claims description 4
• 108010028275 Leukocyte Elastase Proteins 0.000 claims description 4
• 101000794562 Naegleria gruberi Calmodulin, flagellar Proteins 0.000 claims description 4
• 101710116692 Peptidyl-prolyl cis-trans isomerase Proteins 0.000 claims description 4
• 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims description 4
• 101710111198 Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 claims description 4
• 102100026918 Phospholipase A2 Human genes 0.000 claims description 4
• 108010058864 Phospholipases A2 Proteins 0.000 claims description 4
• 108091000080 Phosphotransferase Proteins 0.000 claims description 4
• 108010003541 Platelet Activating Factor Proteins 0.000 claims description 4
• 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 claims description 4
• 102000001253 Protein Kinase Human genes 0.000 claims description 4
• 108090000315 Protein Kinase C Proteins 0.000 claims description 4
• 102000003923 Protein Kinase C Human genes 0.000 claims description 4
• 102100037346 Substance-P receptor Human genes 0.000 claims description 4
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 4
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
• 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
• 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
• 108091008324 binding proteins Proteins 0.000 claims description 4
• 239000002270 dispersing agent Substances 0.000 claims description 4
• 235000013355 food flavoring agent Nutrition 0.000 claims description 4
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
• 238000007917 intracranial administration Methods 0.000 claims description 4
• 230000036210 malignancy Effects 0.000 claims description 4
• 102000020233 phosphotransferase Human genes 0.000 claims description 4
• 239000003380 propellant Substances 0.000 claims description 4
• 102000017953 prostanoid receptors Human genes 0.000 claims description 4
• 108050007059 prostanoid receptors Proteins 0.000 claims description 4
• 150000003839 salts Chemical class 0.000 claims description 4
• 239000002904 solvent Substances 0.000 claims description 4
• IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims description 4
• 229940124530 sulfonamide Drugs 0.000 claims description 4
• 150000003456 sulfonamides Chemical class 0.000 claims description 4
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 4
• 150000003457 sulfones Chemical class 0.000 claims description 4
• 150000003462 sulfoxides Chemical class 0.000 claims description 4
• 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
• 230000002792 vascular Effects 0.000 claims description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
• KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 3
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 3
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims description 3
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 3
• 102000015936 AP-1 transcription factor Human genes 0.000 claims description 3
• 108050004195 AP-1 transcription factor Proteins 0.000 claims description 3
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims description 3
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims description 3
• 108010002913 Asialoglycoproteins Proteins 0.000 claims description 3
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims description 3
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims description 3
• 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 3
• 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 3
• 108010078015 Complement C3b Proteins 0.000 claims description 3
• 101710178508 Defensin 3 Proteins 0.000 claims description 3
• 101710178510 Defensin-2 Proteins 0.000 claims description 3
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 3
• 229920002307 Dextran Polymers 0.000 claims description 3
• 102000030168 Endothelin A Receptor Human genes 0.000 claims description 3
• 108010090549 Endothelin A Receptor Proteins 0.000 claims description 3
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
• 239000005977 Ethylene Substances 0.000 claims description 3
• 102000006471 Fucosyltransferases Human genes 0.000 claims description 3
• 108010019236 Fucosyltransferases Proteins 0.000 claims description 3
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
• 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 claims description 3
• 241000282412 Homo Species 0.000 claims description 3
• 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 claims description 3
• 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 claims description 3
• 108010017521 Interleukin-11 Receptors Proteins 0.000 claims description 3
• 102000004553 Interleukin-11 Receptors Human genes 0.000 claims description 3
• 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 3
• 102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 3
• 102000004889 Interleukin-6 Human genes 0.000 claims description 3
• 108090001005 Interleukin-6 Proteins 0.000 claims description 3
• 102000005741 Metalloproteases Human genes 0.000 claims description 3
• 108010006035 Metalloproteases Proteins 0.000 claims description 3
• 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims description 3
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims description 3
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims description 3
• 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 3
• 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims description 3
• 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 claims description 3
• 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 claims description 3
• 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims description 3
• 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 claims description 3
• 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 claims description 3
• 108010090804 Streptavidin Proteins 0.000 claims description 3
• 102000004338 Transferrin Human genes 0.000 claims description 3
• 108090000901 Transferrin Proteins 0.000 claims description 3
• 229920004890 Triton X-100 Polymers 0.000 claims description 3
• 239000013504 Triton X-100 Substances 0.000 claims description 3
• CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims description 3
• ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
• RZZPDXZPRHQOCG-UHFFFAOYSA-N [[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound OC1C(O)C(COP([O-])(=O)OP(O)(=O)OCC[N+](C)(C)C)OC1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-UHFFFAOYSA-N 0.000 claims description 3
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
• KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims description 3
• 229960003159 atovaquone Drugs 0.000 claims description 3
• 229920001400 block copolymer Polymers 0.000 claims description 3
• 239000006172 buffering agent Substances 0.000 claims description 3
• 239000000969 carrier Substances 0.000 claims description 3
• 229960001231 choline Drugs 0.000 claims description 3
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
• 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 3
• 150000001982 diacylglycerols Chemical class 0.000 claims description 3
• 229940120503 dihydroxyacetone Drugs 0.000 claims description 3
• 150000002031 dolichols Chemical class 0.000 claims description 3
• SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims description 3
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 3
• 238000002513 implantation Methods 0.000 claims description 3
• 238000007918 intramuscular administration Methods 0.000 claims description 3
• 229940067606 lecithin Drugs 0.000 claims description 3
• 239000000787 lecithin Substances 0.000 claims description 3
• 235000010445 lecithin Nutrition 0.000 claims description 3
• AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 3
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 3
• 229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
• 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
• 239000006014 omega-3 oil Substances 0.000 claims description 3
• 210000000056 organ Anatomy 0.000 claims description 3
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
• 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
• 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
• 229950004354 phosphorylcholine Drugs 0.000 claims description 3
• PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims description 3
• 229920001451 polypropylene glycol Polymers 0.000 claims description 3
• 229960002847 prasterone Drugs 0.000 claims description 3
• 239000003755 preservative agent Substances 0.000 claims description 3
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 3
• 239000007921 spray Substances 0.000 claims description 3
• LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 3
• 229940124597 therapeutic agent Drugs 0.000 claims description 3
• 239000012581 transferrin Substances 0.000 claims description 3
• 150000003669 ubiquinones Chemical class 0.000 claims description 3
• 229920002554 vinyl polymer Polymers 0.000 claims description 3
• 239000000341 volatile oil Substances 0.000 claims description 3
• KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 2
• CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 2
• 102000053642 Catalytic RNA Human genes 0.000 claims description 2
• 108090000994 Catalytic RNA Proteins 0.000 claims description 2
• 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 2
• 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 2
• 108091026890 Coding region Proteins 0.000 claims description 2
• 101710178505 Defensin-1 Proteins 0.000 claims description 2
• 102000013128 Endothelin B Receptor Human genes 0.000 claims description 2
• 108010090557 Endothelin B Receptor Proteins 0.000 claims description 2
• 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 claims description 2
• 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 2
• 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 2
• 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 2
• 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 claims description 2
• 108091005682 Receptor kinases Proteins 0.000 claims description 2
• 239000012051 hydrophobic carrier Substances 0.000 claims description 2
• 238000007913 intrathecal administration Methods 0.000 claims description 2
• 239000013081 microcrystal Substances 0.000 claims description 2
• 239000002674 ointment Substances 0.000 claims description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• 108091092562 ribozyme Proteins 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• 230000002194 synthesizing effect Effects 0.000 claims description 2
• 239000000839 emulsion Substances 0.000 claims 7
• 230000037396 body weight Effects 0.000 claims 6
• 102000040430 polynucleotide Human genes 0.000 claims 6
• 108091033319 polynucleotide Proteins 0.000 claims 6
• 239000002157 polynucleotide Substances 0.000 claims 6
• 239000003921 oil Substances 0.000 claims 5
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
• 102000000646 Interleukin-3 Human genes 0.000 claims 3
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 3
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 3
• 230000000415 inactivating effect Effects 0.000 claims 3
• 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 claims 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
• PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 claims 3
• 150000003568 thioethers Chemical class 0.000 claims 3
• 102000007471 Adenosine A2A receptor Human genes 0.000 claims 2
• 108010085277 Adenosine A2A receptor Proteins 0.000 claims 2
• 108091029430 CpG site Proteins 0.000 claims 2
• 239000003086 colorant Substances 0.000 claims 2
• 239000000945 filler Substances 0.000 claims 2
• 239000003960 organic solvent Substances 0.000 claims 2
• 108091008399 peptide binding proteins Proteins 0.000 claims 2
• 108010011903 peptide receptors Proteins 0.000 claims 2
• 102000014187 peptide receptors Human genes 0.000 claims 2
• 230000000069 prophylactic effect Effects 0.000 claims 2
• 239000000018 receptor agonist Substances 0.000 claims 2
• 229940044601 receptor agonist Drugs 0.000 claims 2
• 238000013268 sustained release Methods 0.000 claims 2
• 239000012730 sustained-release form Substances 0.000 claims 2
• 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
• 102000003858 Chymases Human genes 0.000 claims 1
• 102000016799 Leukocyte elastase Human genes 0.000 claims 1
• 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 1
• 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
• 235000021314 Palmitic acid Nutrition 0.000 claims 1
• 102000007078 STAT Transcription Factors Human genes 0.000 claims 1
• 108010072819 STAT Transcription Factors Proteins 0.000 claims 1
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
• 230000003266 anti-allergic effect Effects 0.000 claims 1
• 239000006071 cream Substances 0.000 claims 1
• 229940104302 cytosine Drugs 0.000 claims 1
• 239000008298 dragée Substances 0.000 claims 1
• 239000002702 enteric coating Substances 0.000 claims 1
• 238000009505 enteric coating Methods 0.000 claims 1
• 239000000499 gel Substances 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 239000007972 injectable composition Substances 0.000 claims 1
• 230000001035 methylating effect Effects 0.000 claims 1
• ITFGZZGYXVHOOU-UHFFFAOYSA-N n,n-dimethylmethanamine;methyl hydrogen sulfate Chemical compound C[NH+](C)C.COS([O-])(=O)=O ITFGZZGYXVHOOU-UHFFFAOYSA-N 0.000 claims 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
• 230000001737 promoting effect Effects 0.000 claims 1
• 229920002477 rna polymer Polymers 0.000 claims 1
• 239000000829 suppository Substances 0.000 claims 1
• 239000003826 tablet Substances 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 33
• 241000283973 Oryctolagus cuniculus Species 0.000 description 33
• 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 24
• 102100021954 Alpha-tubulin N-acetyltransferase 1 Human genes 0.000 description 22
• 101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 21
• BZSALXKCVOJCJJ-IPEMHBBOSA-N (4s)-4-[[(2s)-2-acetamido-3-methylbutanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(2s,3r)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy Chemical compound CC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 BZSALXKCVOJCJJ-IPEMHBBOSA-N 0.000 description 19
• 108700010674 N-acetylVal-Nle(7,8)- allatotropin (5-13) Proteins 0.000 description 19
• 102000009346 Adenosine receptors Human genes 0.000 description 17
• 108050000203 Adenosine receptors Proteins 0.000 description 17
• 238000002474 experimental method Methods 0.000 description 17
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 15
• 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 14
• 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 14
• 230000000172 allergic effect Effects 0.000 description 14
• 208000010668 atopic eczema Diseases 0.000 description 14
• 239000011780 sodium chloride Substances 0.000 description 14
• SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 13
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 13
• 210000001519 tissue Anatomy 0.000 description 13
• 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 12
• 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 12
• 150000003838 adenosines Chemical class 0.000 description 12
• 230000027455 binding Effects 0.000 description 12
• 230000010083 bronchial hyperresponsiveness Effects 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 12
• 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 11
• 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 11
• 108091081024 Start codon Proteins 0.000 description 11
• 238000005259 measurement Methods 0.000 description 11
• 150000004713 phosphodiesters Chemical group 0.000 description 11
• JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 10
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
• 101001109571 Pan troglodytes NPC intracellular cholesterol transporter 2 Proteins 0.000 description 10
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 10
• FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 9
• 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 9
• 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 description 9
• 102100029812 Protein S100-A12 Human genes 0.000 description 9
• 101710110949 Protein S100-A12 Proteins 0.000 description 9
• 102100032442 Protein S100-A8 Human genes 0.000 description 9
• 238000013461 design Methods 0.000 description 9
• 230000029058 respiratory gaseous exchange Effects 0.000 description 9
• BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 8
• FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 8
• 101100223766 Bacillus subtilis (strain 168) des gene Proteins 0.000 description 8
• 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 8
• 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 8
• 108010073816 IgE Receptors Proteins 0.000 description 8
• 101150097617 desA gene Proteins 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 230000000241 respiratory effect Effects 0.000 description 8
• 108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 8
• KZFMOINJHMONLW-FOCLMDBBSA-N (2e)-4,7-dichloro-2-(4,7-dichloro-3-oxo-1-benzothiophen-2-ylidene)-1-benzothiophen-3-one Chemical compound S\1C(C(=CC=C2Cl)Cl)=C2C(=O)C/1=C1/C(=O)C(C(Cl)=CC=C2Cl)=C2S1 KZFMOINJHMONLW-FOCLMDBBSA-N 0.000 description 7
• ZDSRFXVZVHSYMA-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 ZDSRFXVZVHSYMA-CMOCDZPBSA-N 0.000 description 7
• JEOQACOXAOEPLX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSCN1.OC(=O)[C@@H](N)CCCN=C(N)N JEOQACOXAOEPLX-WCCKRBBISA-N 0.000 description 7
• JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 7
• IPYJWACEFWLBMV-UHFFFAOYSA-N 2-(1h-indol-3-ylmethyl)-1,3-thiazolidine-4-carboxylic acid Chemical compound N1C(C(=O)O)CSC1CC1=CNC2=CC=CC=C12 IPYJWACEFWLBMV-UHFFFAOYSA-N 0.000 description 7
• JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 7
• 241000726103 Atta Species 0.000 description 7
• FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 7
• 101100175482 Glycine max CG-3 gene Proteins 0.000 description 7
• OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 7
• 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 7
• 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 7
• 108010022394 Threonine synthase Proteins 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 108010068794 tyrosyl-tyrosyl-glutamyl-glutamic acid Proteins 0.000 description 7
• YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 6
• BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 6
• 108050001736 Bradykinin receptor Proteins 0.000 description 6
• 102000010183 Bradykinin receptor Human genes 0.000 description 6
• 101000946068 Caenorhabditis elegans Ceramide glucosyltransferase 3 Proteins 0.000 description 6
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 6
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 6
• 101000856513 Homo sapiens Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Proteins 0.000 description 6
• 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 6
• 102100025509 Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Human genes 0.000 description 6
• 102100039064 Interleukin-3 Human genes 0.000 description 6
• 208000019693 Lung disease Diseases 0.000 description 6
• FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 6
• 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 6
• 239000013566 allergen Substances 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 238000009396 hybridization Methods 0.000 description 6
• 229940096397 interleukin-8 Drugs 0.000 description 6
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 5
• AWXGSYPUMWKTBR-UHFFFAOYSA-N 4-carbazol-9-yl-n,n-bis(4-carbazol-9-ylphenyl)aniline Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(N(C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=C1 AWXGSYPUMWKTBR-UHFFFAOYSA-N 0.000 description 5
• 108060003345 Adrenergic Receptor Proteins 0.000 description 5
• 102000017910 Adrenergic receptor Human genes 0.000 description 5
• 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 5
• 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 5
• 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 5
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 5
• 201000003883 Cystic fibrosis Diseases 0.000 description 5
• 108020004414 DNA Proteins 0.000 description 5
• 102100033264 Geranylgeranyl transferase type-1 subunit beta Human genes 0.000 description 5
• 101001071129 Homo sapiens Geranylgeranyl transferase type-1 subunit beta Proteins 0.000 description 5
• 101000837344 Homo sapiens T-cell leukemia translocation-altered gene protein Proteins 0.000 description 5
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 5
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 5
• 102100033174 Neutrophil elastase Human genes 0.000 description 5
• 102000004316 Oxidoreductases Human genes 0.000 description 5
• 108090000854 Oxidoreductases Proteins 0.000 description 5
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
• 102100028692 T-cell leukemia translocation-altered gene protein Human genes 0.000 description 5
• 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 5
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 5
• 238000000540 analysis of variance Methods 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 210000000621 bronchi Anatomy 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 229960001340 histamine Drugs 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 238000011555 rabbit model Methods 0.000 description 5
• 101150075675 tatC gene Proteins 0.000 description 5
• 208000002918 testicular germ cell tumor Diseases 0.000 description 5
• QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 4
• 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 4
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
• 108010033174 Deoxycytidine kinase Proteins 0.000 description 4
• 102100029588 Deoxycytidine kinase Human genes 0.000 description 4
• 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 4
• 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 4
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 4
• 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 4
• 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 4
• 101000605015 Homo sapiens Putative L-type amino acid transporter 1-like protein IMAA Proteins 0.000 description 4
• 108010017511 Interleukin-13 Receptors Proteins 0.000 description 4
• 102000004559 Interleukin-13 Receptors Human genes 0.000 description 4
• 101800003050 Interleukin-16 Proteins 0.000 description 4
• 102000049772 Interleukin-16 Human genes 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
• 102100038209 Putative L-type amino acid transporter 1-like protein IMAA Human genes 0.000 description 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
• 102000000505 Ribonucleotide Reductases Human genes 0.000 description 4
• 108010041388 Ribonucleotide Reductases Proteins 0.000 description 4
• 102400000096 Substance P Human genes 0.000 description 4
• 101800003906 Substance P Proteins 0.000 description 4
• 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 4
• 102000006601 Thymidine Kinase Human genes 0.000 description 4
• 108020004440 Thymidine kinase Proteins 0.000 description 4
• 210000005091 airway smooth muscle Anatomy 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 229960000836 amitriptyline Drugs 0.000 description 4
• 206010006451 bronchitis Diseases 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 101150062912 cct3 gene Proteins 0.000 description 4
• 101150117300 ctrC gene Proteins 0.000 description 4
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 229940028885 interleukin-4 Drugs 0.000 description 4
• 229940100602 interleukin-5 Drugs 0.000 description 4
• 239000003595 mist Substances 0.000 description 4
• 210000000214 mouth Anatomy 0.000 description 4
• 210000000440 neutrophil Anatomy 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 208000023504 respiratory system disease Diseases 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 3
• DMJXRYSGXCLCFP-LBPRGKRZSA-N (3s)-n-tert-butyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide Chemical compound C1=CC=C2CN[C@H](C(=O)NC(C)(C)C)CC2=C1 DMJXRYSGXCLCFP-LBPRGKRZSA-N 0.000 description 3
• 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 3
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
• 108010041368 Adenosine A2 Receptors Proteins 0.000 description 3
• 102000000506 Adenosine A2 Receptors Human genes 0.000 description 3
• 101800004538 Bradykinin Proteins 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 206010006458 Bronchitis chronic Diseases 0.000 description 3
• 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 3
• PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 3
• 241000219357 Cactaceae Species 0.000 description 3
• 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 3
• 102100024539 Chymase Human genes 0.000 description 3
• 102000000541 Defensins Human genes 0.000 description 3
• 108010002069 Defensins Proteins 0.000 description 3
• 102000017930 EDNRB Human genes 0.000 description 3
• 101150001833 EDNRB gene Proteins 0.000 description 3
• 102000057955 Eosinophil Cationic Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 102100024375 Gamma-glutamylaminecyclotransferase Human genes 0.000 description 3
• 101710201613 Gamma-glutamylaminecyclotransferase Proteins 0.000 description 3
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
• 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 description 3
• 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 3
• 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 3
• 208000033229 Immune-mediated cerebellar ataxia Diseases 0.000 description 3
• 102000003814 Interleukin-10 Human genes 0.000 description 3
• 108090000174 Interleukin-10 Proteins 0.000 description 3
• 108010017515 Interleukin-12 Receptors Proteins 0.000 description 3
• 102000004560 Interleukin-12 Receptors Human genes 0.000 description 3
• 108010038498 Interleukin-7 Receptors Proteins 0.000 description 3
• 102000010782 Interleukin-7 Receptors Human genes 0.000 description 3
• 102100035792 Kininogen-1 Human genes 0.000 description 3
• 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 3
• 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 3
• 101710163270 Nuclease Proteins 0.000 description 3
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
• 102000015433 Prostaglandin Receptors Human genes 0.000 description 3
• 108010050183 Prostaglandin Receptors Proteins 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 239000000150 Sympathomimetic Substances 0.000 description 3
• 102000005497 Thymidylate Synthase Human genes 0.000 description 3
• YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 229960004538 alprazolam Drugs 0.000 description 3
• 108010025592 aminoadipoyl-cysteinyl-allylglycine Proteins 0.000 description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 239000002249 anxiolytic agent Substances 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 229960004782 chlordiazepoxide Drugs 0.000 description 3
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
• 208000007451 chronic bronchitis Diseases 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 229960003529 diazepam Drugs 0.000 description 3
• 229960001259 diclofenac Drugs 0.000 description 3
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
• 102000004419 dihydrofolate reductase Human genes 0.000 description 3
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 3
• 239000000428 dust Substances 0.000 description 3
• 230000002526 effect on cardiovascular system Effects 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229940076144 interleukin-10 Drugs 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 229960004391 lorazepam Drugs 0.000 description 3
• 201000005249 lung adenocarcinoma Diseases 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 210000003928 nasal cavity Anatomy 0.000 description 3
• 238000007427 paired t-test Methods 0.000 description 3
• 239000002831 pharmacologic agent Substances 0.000 description 3
• 229960002695 phenobarbital Drugs 0.000 description 3
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
• 229920000573 polyethylene Polymers 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 230000009325 pulmonary function Effects 0.000 description 3
• 208000002815 pulmonary hypertension Diseases 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000001975 sympathomimetic effect Effects 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 230000001131 transforming effect Effects 0.000 description 3
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
• VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 2
• FQRHOOHLUYHMGG-BTJKTKAUSA-N 3-(2-acetylphenothiazin-10-yl)propyl-dimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-BTJKTKAUSA-N 0.000 description 2
• LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 2
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
• 101150026261 ACT7 gene Proteins 0.000 description 2
• 241000023308 Acca Species 0.000 description 2
• 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 2
• 102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 2
• 102100036664 Adenosine deaminase Human genes 0.000 description 2
• 102100038154 Agouti-signaling protein Human genes 0.000 description 2
• 208000000884 Airway Obstruction Diseases 0.000 description 2
• 239000005995 Aluminium silicate Substances 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 2
• 102000004499 CCR3 Receptors Human genes 0.000 description 2
• 108010017316 CCR3 Receptors Proteins 0.000 description 2
• 108090000617 Cathepsin G Proteins 0.000 description 2
• 102100025975 Cathepsin G Human genes 0.000 description 2
• UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 2
• 108010009685 Cholinergic Receptors Proteins 0.000 description 2
• 241000543381 Cliftonia monophylla Species 0.000 description 2
• 241000238713 Dermatophagoides farinae Species 0.000 description 2
• 102000015554 Dopamine receptor Human genes 0.000 description 2
• 108050004812 Dopamine receptor Proteins 0.000 description 2
• 108050009340 Endothelin Proteins 0.000 description 2
• 102000002045 Endothelin Human genes 0.000 description 2
• 102400000686 Endothelin-1 Human genes 0.000 description 2
• 101710204837 Envelope small membrane protein Proteins 0.000 description 2
• 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
• 101710191360 Eosinophil cationic protein Proteins 0.000 description 2
• 102100028471 Eosinophil peroxidase Human genes 0.000 description 2
• 108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 description 2
• 102000013888 Eosinophil-Derived Neurotoxin Human genes 0.000 description 2
• LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 2
• 102000005915 GABA Receptors Human genes 0.000 description 2
• 108010005551 GABA Receptors Proteins 0.000 description 2
• 241001123946 Gaga Species 0.000 description 2
• 108010063919 Glucagon Receptors Proteins 0.000 description 2
• 102100040890 Glucagon receptor Human genes 0.000 description 2
• WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• 108010014095 Histidine decarboxylase Proteins 0.000 description 2
• 102100037095 Histidine decarboxylase Human genes 0.000 description 2
• 101100492429 Homo sapiens ASIP gene Proteins 0.000 description 2
• 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 2
• 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 2
• 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
• 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 2
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
• 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 2
• 101000969630 Homo sapiens Monocarboxylate transporter 10 Proteins 0.000 description 2
• 101000577696 Homo sapiens Proline-rich transmembrane protein 2 Proteins 0.000 description 2
• 101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 2
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
• 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 2
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 108010001127 Insulin Receptor Proteins 0.000 description 2
• 102000003746 Insulin Receptor Human genes 0.000 description 2
• 102000003777 Interleukin-1 beta Human genes 0.000 description 2
• 108090000193 Interleukin-1 beta Proteins 0.000 description 2
• 108010017550 Interleukin-10 Receptors Proteins 0.000 description 2
• 102000004551 Interleukin-10 Receptors Human genes 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000003816 Interleukin-13 Human genes 0.000 description 2
• 108090000176 Interleukin-13 Proteins 0.000 description 2
• 102000003812 Interleukin-15 Human genes 0.000 description 2
• 108090000172 Interleukin-15 Proteins 0.000 description 2
• 108010017535 Interleukin-15 Receptors Proteins 0.000 description 2
• 102000004556 Interleukin-15 Receptors Human genes 0.000 description 2
• 102000000704 Interleukin-7 Human genes 0.000 description 2
• 108010002586 Interleukin-7 Proteins 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 102100023758 Leukotriene C4 synthase Human genes 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 102100035304 Lymphotactin Human genes 0.000 description 2
• MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 2
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
• 102100021425 Monocarboxylate transporter 10 Human genes 0.000 description 2
• 101100219997 Mus musculus Ccr1 gene Proteins 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• 102000002003 Neurokinin-3 Receptors Human genes 0.000 description 2
• 108010040716 Neurokinin-3 Receptors Proteins 0.000 description 2
• 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 2
• 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
• MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 2
• 206010036618 Premenstrual syndrome Diseases 0.000 description 2
• 102100028840 Proline-rich transmembrane protein 2 Human genes 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 101710088839 Replication initiation protein Proteins 0.000 description 2
• 241000220010 Rhode Species 0.000 description 2
• 244000112572 Sesbania bispinosa Species 0.000 description 2
• 235000010896 Sesbania bispinosa Nutrition 0.000 description 2
• 235000015392 Sesbania grandiflora Nutrition 0.000 description 2
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
• ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
• 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 2
• 240000002033 Tacca leontopetaloides Species 0.000 description 2
• 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
• 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
• ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 2
• 229960001946 acepromazine maleate Drugs 0.000 description 2
• 102000034337 acetylcholine receptors Human genes 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 229940121359 adenosine receptor antagonist Drugs 0.000 description 2
• 235000012211 aluminium silicate Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
• 230000001195 anabolic effect Effects 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 102000001307 androgen receptors Human genes 0.000 description 2
• 108010080146 androgen receptors Proteins 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 229960002729 bromazepam Drugs 0.000 description 2
• ZRIHAIZYIMGOAB-UHFFFAOYSA-N butabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 2
• 210000001715 carotid artery Anatomy 0.000 description 2
• WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 229960002688 choline salicylate Drugs 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 229940035811 conjugated estrogen Drugs 0.000 description 2
• UHDGCWIWMRVCDJ-XVFCMESISA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 2
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
• 229960000616 diflunisal Drugs 0.000 description 2
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
• 229960000520 diphenhydramine Drugs 0.000 description 2
• 230000002222 downregulating effect Effects 0.000 description 2
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• 102000015694 estrogen receptors Human genes 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 229960005293 etodolac Drugs 0.000 description 2
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 210000001105 femoral artery Anatomy 0.000 description 2
• 210000003191 femoral vein Anatomy 0.000 description 2
• 229960001419 fenoprofen Drugs 0.000 description 2
• 229960002390 flurbiprofen Drugs 0.000 description 2
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 229960002158 halazepam Drugs 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 102000055276 human IL3 Human genes 0.000 description 2
• 102000055229 human IL4 Human genes 0.000 description 2
• 102000055228 human IL5 Human genes 0.000 description 2
• 102000052611 human IL6 Human genes 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• 229960000930 hydroxyzine Drugs 0.000 description 2
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 229960000905 indomethacin Drugs 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 206010022437 insomnia Diseases 0.000 description 2
• 229940117681 interleukin-12 Drugs 0.000 description 2
• 108010052754 interleukin-14 receptor Proteins 0.000 description 2
• 229940100994 interleukin-7 Drugs 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 210000004731 jugular vein Anatomy 0.000 description 2
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
• 229960000991 ketoprofen Drugs 0.000 description 2
• 229960004752 ketorolac Drugs 0.000 description 2
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 210000000867 larynx Anatomy 0.000 description 2
• 239000004816 latex Substances 0.000 description 2
• 229920000126 latex Polymers 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
• 108010087711 leukotriene-C4 synthase Proteins 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 229940072082 magnesium salicylate Drugs 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 108700025647 major vault Proteins 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 229940013798 meclofenamate Drugs 0.000 description 2
• 108010017026 medullasin Proteins 0.000 description 2
• 229960003464 mefenamic acid Drugs 0.000 description 2
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 2
• 229940042053 methotrimeprazine Drugs 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 230000003551 muscarinic effect Effects 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
• 229960004535 oxazepam Drugs 0.000 description 2
• ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 2
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 230000001499 parasympathomimetic effect Effects 0.000 description 2
• 229960002296 paroxetine Drugs 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 229960000762 perphenazine Drugs 0.000 description 2
• 150000008105 phosphatidylcholines Chemical class 0.000 description 2
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 229960004856 prazepam Drugs 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 230000008695 pulmonary vasoconstriction Effects 0.000 description 2
• 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 229960000953 salsalate Drugs 0.000 description 2
• 229960002060 secobarbital Drugs 0.000 description 2
• KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 2
• 239000000932 sedative agent Substances 0.000 description 2
• 229940125723 sedative agent Drugs 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 229960004025 sodium salicylate Drugs 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 238000011287 therapeutic dose Methods 0.000 description 2
• 102000004217 thyroid hormone receptors Human genes 0.000 description 2
• 108090000721 thyroid hormone receptors Proteins 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
• WYWZCALINPVKJW-KOCZGPIPSA-N (2s,4s)-2-[[(3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indole-2-carbonyl]-[(2r,4s)-4-propoxypyrrolidine-2-carbonyl]amino]-2-[1-[(2s)-1-[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidin-2-yl]-4 Chemical compound C1[C@H](OCCC)CN[C@H]1C(=O)N([C@](C(CCN=C(N)N)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](N)CCCN=C(N)N)(C(O)=O)C(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H]1NCC(O)C1)C(=O)C1N[C@H]2CCCC[C@H]2C1 WYWZCALINPVKJW-KOCZGPIPSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• OQCFWECOQNPQCG-UHFFFAOYSA-N 1,3,4,8-tetrahydropyrimido[4,5-c]oxazin-7-one Chemical compound C1CONC2=C1C=NC(=O)N2 OQCFWECOQNPQCG-UHFFFAOYSA-N 0.000 description 1
• HTFVKMHFUBCIMH-UHFFFAOYSA-N 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione Chemical compound IN1C(=O)N(I)C(=O)N(I)C1=O HTFVKMHFUBCIMH-UHFFFAOYSA-N 0.000 description 1
• ASWBNKHCZGQVJV-HSZRJFAPSA-O 1-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-HSZRJFAPSA-O 0.000 description 1
• BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
• KAJBSGLXSREIHP-UHFFFAOYSA-N 2,2-bis[(2-sulfanylacetyl)oxymethyl]butyl 2-sulfanylacetate Chemical compound SCC(=O)OCC(CC)(COC(=O)CS)COC(=O)CS KAJBSGLXSREIHP-UHFFFAOYSA-N 0.000 description 1
• KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
• ZVVAINSYJGRDTR-TYLGTTGKSA-N 2-(1-benzofuran-4-yl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide;hydrochloride Chemical compound Cl.C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=3C=COC=3C=CC=2)C[C@]21CCCO2 ZVVAINSYJGRDTR-TYLGTTGKSA-N 0.000 description 1
• NYPYHUZRZVSYKL-UHFFFAOYSA-N 2-azaniumyl-3-(4-hydroxy-3,5-diiodophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
• 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
• UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 101710190443 Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 102000007470 Adenosine A2B Receptor Human genes 0.000 description 1
• 108010085273 Adenosine A2B receptor Proteins 0.000 description 1
• 229940122086 Adenosine A2a receptor agonist Drugs 0.000 description 1
• 108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
• 102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
• 101001015038 Albizia kalkora Kunitz-type trypsin inhibitor alpha chain Proteins 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 101100116664 Arabidopsis thaliana ATTI1 gene Proteins 0.000 description 1
• 101000965157 Arabidopsis thaliana Acyl-CoA hydrolase 1 Proteins 0.000 description 1
• 101100219344 Arabidopsis thaliana CAT7 gene Proteins 0.000 description 1
• 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 1
• 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 108010040471 CC Chemokines Proteins 0.000 description 1
• 102000001902 CC Chemokines Human genes 0.000 description 1
• HQOWCDPFDSRYRO-CDKVKFQUSA-N CCCCCCc1ccc(cc1)C1(c2cc3-c4sc5cc(\C=C6/C(=O)c7ccccc7C6=C(C#N)C#N)sc5c4C(c3cc2-c2sc3cc(C=C4C(=O)c5ccccc5C4=C(C#N)C#N)sc3c12)(c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1 Chemical compound CCCCCCc1ccc(cc1)C1(c2cc3-c4sc5cc(\C=C6/C(=O)c7ccccc7C6=C(C#N)C#N)sc5c4C(c3cc2-c2sc3cc(C=C4C(=O)c5ccccc5C4=C(C#N)C#N)sc3c12)(c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1 HQOWCDPFDSRYRO-CDKVKFQUSA-N 0.000 description 1
• 102000004500 CCR1 Receptors Human genes 0.000 description 1
• 101150071146 COX2 gene Proteins 0.000 description 1
• 102100022443 CXADR-like membrane protein Human genes 0.000 description 1
• 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
• 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
• 101100371648 Caenorhabditis elegans usp-14 gene Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
• 102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 241000283153 Cetacea Species 0.000 description 1
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
• 102000001493 Cyclophilins Human genes 0.000 description 1
• 108010068682 Cyclophilins Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 102000010180 Endothelin receptor Human genes 0.000 description 1
• 108050001739 Endothelin receptor Proteins 0.000 description 1
• 108700016749 Eosinophil Cationic Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
• RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
• DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 description 1
• 101000783756 Homo sapiens Adenosine receptor A2b Proteins 0.000 description 1
• 101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 1
• 101000753184 Homo sapiens Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 1
• 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
• 101001095043 Homo sapiens Bone marrow proteoglycan Proteins 0.000 description 1
• 101000777564 Homo sapiens C-C chemokine receptor type 1 Proteins 0.000 description 1
• 101000901723 Homo sapiens CXADR-like membrane protein Proteins 0.000 description 1
• 101000933179 Homo sapiens Cathepsin G Proteins 0.000 description 1
• 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
• 101000925493 Homo sapiens Endothelin-1 Proteins 0.000 description 1
• 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
• 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
• 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
• 101000711744 Homo sapiens Non-secretory ribonuclease Proteins 0.000 description 1
• 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
• 101000795074 Homo sapiens Tryptase alpha/beta-1 Proteins 0.000 description 1
• 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
• 108060001621 Isoprenylcysteine carboxyl methyltransferase Proteins 0.000 description 1
• 101000894788 Lachesana tarabaevi Cytoinsectotoxin-3 Proteins 0.000 description 1
• GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
• JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• 108091027974 Mature messenger RNA Proteins 0.000 description 1
• PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
• YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
• 206010027304 Menopausal symptoms Diseases 0.000 description 1
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
• NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
• PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
• RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 108010058850 NPC 17731 Proteins 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• 108050000302 Neurokinin receptors Proteins 0.000 description 1
• 102000009493 Neurokinin receptors Human genes 0.000 description 1
• 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 239000008896 Opium Substances 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
• 101150000187 PTGS2 gene Proteins 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
• 206010034759 Petit mal epilepsy Diseases 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
• 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
• 102100035033 Protein-S-isoprenylcysteine O-methyltransferase Human genes 0.000 description 1
• 241000238711 Pyroglyphidae Species 0.000 description 1
• IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
• 241001282738 Racta Species 0.000 description 1
• 101100112350 Rattus norvegicus Cat gene Proteins 0.000 description 1
• 101100236310 Rattus norvegicus Gaa gene Proteins 0.000 description 1
• 101100316024 Rattus norvegicus Uggt1 gene Proteins 0.000 description 1
• 108091007187 Reductases Proteins 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 102100029639 Tryptase alpha/beta-1 Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000013567 aeroallergen Substances 0.000 description 1
• 239000004479 aerosol dispenser Substances 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 230000008371 airway function Effects 0.000 description 1
• 229960003790 alimemazine Drugs 0.000 description 1
• 229960001301 amobarbital Drugs 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000001088 anti-asthma Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 239000000924 antiasthmatic agent Substances 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 229960003153 aprobarbital Drugs 0.000 description 1
• UORJNBVJVRLXMQ-UHFFFAOYSA-N aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 229940072698 ativan Drugs 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• 229940092732 belladonna alkaloid Drugs 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940125388 beta agonist Drugs 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 1
• 238000009530 blood pressure measurement Methods 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
• 229960001736 buprenorphine Drugs 0.000 description 1
• 229960002495 buspirone Drugs 0.000 description 1
• QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
• 229940015694 butabarbital Drugs 0.000 description 1
• 229960002810 chlormezanone Drugs 0.000 description 1
• WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
• KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical class F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002896 clonidine Drugs 0.000 description 1
• 229960004362 clorazepate Drugs 0.000 description 1
• XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 230000002517 constrictor effect Effects 0.000 description 1
• 230000001120 cytoprotective effect Effects 0.000 description 1
• 229960000766 danazol Drugs 0.000 description 1
• POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
• 229960004193 dextropropoxyphene Drugs 0.000 description 1
• 229960003461 dezocine Drugs 0.000 description 1
• VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
• 229960000920 dihydrocodeine Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229960005426 doxepin Drugs 0.000 description 1
• HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
• 229960005178 doxylamine Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 229940098766 effexor Drugs 0.000 description 1
• 229940011681 elavil Drugs 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 108091007231 endothelial receptors Proteins 0.000 description 1
• QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
• XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 1
• 229960004943 ergotamine Drugs 0.000 description 1
• XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
• 229960002336 estazolam Drugs 0.000 description 1
• CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960005416 estradiol cypionate Drugs 0.000 description 1
• 229960004766 estradiol valerate Drugs 0.000 description 1
• 229960003399 estrone Drugs 0.000 description 1
• 229940081345 estropipate Drugs 0.000 description 1
• HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
• 229960002568 ethinylestradiol Drugs 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 229960001582 fenfluramine Drugs 0.000 description 1
• 239000010419 fine particle Substances 0.000 description 1
• 229960003240 floctafenine Drugs 0.000 description 1
• 229960000676 flunisolide Drugs 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• 229960003528 flurazepam Drugs 0.000 description 1
• SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
• 229960002107 fluvoxamine maleate Drugs 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960002972 glutethimide Drugs 0.000 description 1
• 230000001456 gonadotroph Effects 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000009532 heart rate measurement Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 102000055905 human ADORA2A Human genes 0.000 description 1
• 102000055126 human ADORA2B Human genes 0.000 description 1
• 102000046278 human ADORA3 Human genes 0.000 description 1
• 102000046157 human CSF2 Human genes 0.000 description 1
• 102000055647 human CSF2RB Human genes 0.000 description 1
• 102000052896 human CTSG Human genes 0.000 description 1
• 102000052502 human ELANE Human genes 0.000 description 1
• 102000056236 human PRG2 Human genes 0.000 description 1
• 102000043345 human RNASE3 Human genes 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
• 229960001410 hydromorphone Drugs 0.000 description 1
• 230000004047 hyperresponsiveness Effects 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
• 229960004184 ketamine hydrochloride Drugs 0.000 description 1
• 229960004423 ketazolam Drugs 0.000 description 1
• PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
• 229960003406 levorphanol Drugs 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 229960000423 loxapine Drugs 0.000 description 1
• XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
• 229940009622 luvox Drugs 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
• 229960004090 maprotiline Drugs 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229960004616 medroxyprogesterone Drugs 0.000 description 1
• FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
• 229960003987 melatonin Drugs 0.000 description 1
• DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• 201000003102 mental depression Diseases 0.000 description 1
• ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 1
• 229960004815 meprobamate Drugs 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229940071648 metered dose inhaler Drugs 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• 229960002683 methohexital Drugs 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 229960001703 methylphenobarbital Drugs 0.000 description 1
• 229960003793 midazolam Drugs 0.000 description 1
• DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
• 230000033607 mismatch repair Effects 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 239000004570 mortar (masonry) Substances 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
• 229960000805 nalbuphine Drugs 0.000 description 1
• 230000003533 narcotic effect Effects 0.000 description 1
• 229960001454 nitrazepam Drugs 0.000 description 1
• KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 208000014055 occupational lung disease Diseases 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 235000021313 oleic acid Nutrition 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 229960001027 opium Drugs 0.000 description 1
• 229940127234 oral contraceptive Drugs 0.000 description 1
• 239000003539 oral contraceptive agent Substances 0.000 description 1
• 229960002739 oxaprozin Drugs 0.000 description 1
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229960005118 oxymorphone Drugs 0.000 description 1
• 230000001734 parasympathetic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
• 229960005301 pentazocine Drugs 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 230000036581 peripheral resistance Effects 0.000 description 1
• 229960000482 pethidine Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 238000001126 phototherapy Methods 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 102000030769 platelet activating factor receptor Human genes 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 229960003910 promethazine Drugs 0.000 description 1
• OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
• 229960004134 propofol Drugs 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 229940035613 prozac Drugs 0.000 description 1
• RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
• 229960001964 quazepam Drugs 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 239000003488 releasing hormone Substances 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 210000005245 right atrium Anatomy 0.000 description 1
• 229960001487 rimexolone Drugs 0.000 description 1
• QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
• 102220093060 rs201570725 Human genes 0.000 description 1
• 102220182974 rs886051886 Human genes 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
• 230000002557 soporific effect Effects 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 229960003188 temazepam Drugs 0.000 description 1
• 229960002871 tenoxicam Drugs 0.000 description 1
• WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
• 101150090882 tgt-1 gene Proteins 0.000 description 1
• XLOMZPUITCYLMJ-UHFFFAOYSA-N thiamylal Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O XLOMZPUITCYLMJ-UHFFFAOYSA-N 0.000 description 1
• 229960001166 thiamylal Drugs 0.000 description 1
• 229960001312 tiaprofenic acid Drugs 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 229960004380 tramadol Drugs 0.000 description 1
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
• 239000003204 tranquilizing agent Substances 0.000 description 1
• 230000002936 tranquilizing effect Effects 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 229960003386 triazolam Drugs 0.000 description 1
• JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 229940072690 valium Drugs 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 229960004688 venlafaxine Drugs 0.000 description 1
• 235000019158 vitamin B6 Nutrition 0.000 description 1
• 239000011726 vitamin B6 Substances 0.000 description 1
• 229940011671 vitamin b6 Drugs 0.000 description 1
• 229940074158 xanax Drugs 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 229940020965 zoloft Drugs 0.000 description 1
• 229960001475 zolpidem Drugs 0.000 description 1
• ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1